502 related articles for article (PubMed ID: 18355324)
1. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Rosenstock J; Sankoh S; List JF
Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
3. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
[TBL] [Abstract][Full Text] [Related]
4. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
[TBL] [Abstract][Full Text] [Related]
6. Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
Jain R
Adv Ther; 2015 Nov; 32(11):1065-84. PubMed ID: 26578430
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
Abe M; Higuchi T; Moriuchi M; Okamura M; Tei R; Nagura C; Takashima H; Kikuchi F; Tomita H; Okada K
Diabetes Res Clin Pract; 2016 Jun; 116():244-52. PubMed ID: 27321342
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
[TBL] [Abstract][Full Text] [Related]
9. Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.
Henry RR; Smith SR; Schwartz SL; Mudaliar SR; Deacon CF; Holst JJ; Duan RY; Chen RS; List JF
Diabetes Obes Metab; 2011 Sep; 13(9):850-8. PubMed ID: 21554520
[TBL] [Abstract][Full Text] [Related]
10. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Campbell RK
Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
[TBL] [Abstract][Full Text] [Related]
11. Saxagliptin (Onglyza) for type 2 diabetes.
Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.
Pan CY; Yang W; Tou C; Gause-Nilsson I; Zhao J
Diabetes Metab Res Rev; 2012 Mar; 28(3):268-75. PubMed ID: 22081481
[TBL] [Abstract][Full Text] [Related]
13. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Matthaei S; Aggarwal N; Garcia-Hernandez P; Iqbal N; Chen H; Johnsson E; Chin A; Hansen L
Diabetes Obes Metab; 2016 Nov; 18(11):1128-1133. PubMed ID: 27403645
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
Hollander PL; Li J; Frederich R; Allen E; Chen R;
Diab Vasc Dis Res; 2011 Apr; 8(2):125-35. PubMed ID: 21562064
[TBL] [Abstract][Full Text] [Related]
15. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Cook W; Minervini G; Bryzinski B; Hirshberg B
Postgrad Med; 2014 Oct; 126(6):19-32. PubMed ID: 25414932
[TBL] [Abstract][Full Text] [Related]
16. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
Bonora E; Bryzinski B; Hirshberg B; Cook W
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):374-9. PubMed ID: 27033025
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Dou J; Ma J; Liu J; Wang C; Johnsson E; Yao H; Zhao J; Pan C
Diabetes Obes Metab; 2018 Mar; 20(3):590-598. PubMed ID: 28926170
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.
Nowicki M; Rychlik I; Haller H; Warren M; Suchower L; Gause-Nilsson I; Schützer KM
Int J Clin Pract; 2011 Dec; 65(12):1230-9. PubMed ID: 21977965
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Rosenstock J; Mathieu C; Chen H; Garcia-Sanchez R; Saraiva GL
Arch Endocrinol Metab; 2018 Aug; 62(4):424-430. PubMed ID: 30304106
[TBL] [Abstract][Full Text] [Related]
20. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
Nowicki M; Rychlik I; Haller H; Warren ML; Suchower L; Gause-Nilsson I;
Diabetes Obes Metab; 2011 Jun; 13(6):523-32. PubMed ID: 21332627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
